An independent committee has
recommended that a late (Phase
III) stage study of a drug developed
by Pharmacyclics and Johnson
& Johnson be stopped early due
to improved overall survival in
patients with chronic lymphocytic
leukemia (CLL).
The drug IMBRUVICA (ibrutinib)
showed a “statistically significant
improvement in progression-free
survival” as well as overall survival
in patients with relapsed or
refractory CLL or small lymphocytic
lymphoma (SLL).
The study involved 391 patients
and was conducted at more than
70 clinical sites in 10 countries,
Pharmacyclics said.
To read more CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jan 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.